Kaupinen Wes 4

What Happened

• Wes Kaupinen, reported as a 10% owner of Palvella Therapeutics (PVLA), was granted a derivative award for 124,603 shares on Feb 5, 2026. The reported acquisition price is $0.00 (total reported value $0), indicating an equity award/option rather than an open‑market purchase.

Key Details

• Transaction date: 2026-02-05; Form 4 filed: 2026-02-09 (filed within required reporting window).
• Transaction type/code: A — Grant/award (derivative security).
• Shares awarded: 124,603; reported price: $0.00; reported cash value: $0.
• Vesting: The award vests in equal monthly installments over 48 months beginning Feb 5, 2026, subject to continuous service (per footnote).
• Post-transaction holdings: The filing does not state total shares beneficially owned after this grant.
• Reporting status: Reporting person is a 10% owner (significant holder), not an open‑market buyer/seller.

Context

• This was a grant of a derivative award (likely options or RSUs) that will convert to vested shares over time; until vesting/exercise those shares are typically not marketable. Grants are commonly part of compensation or long‑term incentive programs and do not by themselves indicate immediate buying or selling intent.